Adaptimmune Reports Third Quarter Financial Results and Business Update
04. November 2021 07:30 ET
|
Adaptimmune Therapeutics plc
- Strategic Collaboration Agreement with Genentech has started after expiration of HSR waiting periods; Adaptimmune set to receive $150 million upfront payment - - SURPASS trial data at ESMO confirms...
Adaptimmune to Report Q3 2021 Financial Results and Business Update on Thursday, November 4, 2021
21. Oktober 2021 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results...
Adaptimmune to Present Data Updates at Upcoming CTOS and SITC Meetings
05. Oktober 2021 08:00 ET
|
Adaptimmune Therapeutics plc
- Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS - - The Company will host its first virtual medical symposium at CTOS - ...
Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
13. September 2021 07:00 ET
|
Adaptimmune Therapeutics plc
- Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers - - Majority of patients...
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
07. September 2021 07:00 ET
|
Adaptimmune Therapeutics plc
- Combining both companies’ cell therapy leadership and expertise, the collaboration covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and the...
Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
05. September 2021 06:15 ET
|
Adaptimmune Therapeutics plc
- One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff - - Data presented today at the International Liver Cancer...
Adaptimmune Reports Second Quarter Financial Results and Business Update
09. August 2021 16:00 ET
|
Adaptimmune Therapeutics plc
- SPEARHEAD-1 data presented at ASCO with overall response rate of 39.3% in synovial sarcoma and MRCLS; on track to file BLA for afami-cel next year - - SURPASS trial data from 23 evaluable patients...
Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021
28. Juli 2021 08:11 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 28, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results...
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
19. Mai 2021 17:00 ET
|
Adaptimmune Therapeutics plc
- Data will support BLA filing for afamitresgene autoleucel next year - - Responses observed across a broad range of antigen expression - - Initial safety and durability are encouraging - ...
First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model
11. Mai 2021 08:00 ET
|
Adaptimmune Therapeutics plc
- Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells - - HiT works as well, or better than, a TRuC...